EPA and DHA Omega-3 Ingredient Market Demand to Increase at a CAGR of 7.2% from 2023 to 2033

According to Fact.MR, a market research and competitive intelligence provider, the global EPA and DHA omega-3 ingredient market is growing at a CAGR of 7.2% and is projected to reach a value of USD 6.13 billion by the end of 2033.

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are unique types of healthy fats found in fatty fish like salmon and certain algae. These fats are crucial for heart health and can enhance mood. What sets EPA and DHA apart is their high bioavailability, making them easier for the human body to utilize compared to other healthy fats. Additionally, they are highly effective in reducing inflammation, which is associated with numerous serious health conditions. DHA, in particular, is vital for the developing brains of infants.

Get Free Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4050

The surge in the EPA and DHA omega-3 ingredient market stems largely from growing consumer awareness of the health advantages linked to these fatty acids. With a heightened focus on well-being, there’s a rising demand for goods that support heart health and cognitive function. Nonetheless, manufacturers encounter hurdles like integrating healthful ingredients into food without altering its flavor or aroma, posing a significant challenge in the market.

Key Takeaways:

• The United States market is experiencing healthy growth due to an increasing health-conscious consumer base and positive regulatory support.
• Pharmaceutical channels are playing a major role in Fish-oil-based nutrient supplement sales.
• The Japanese market is expected to witness high sales due to the high aging population and emphasis on healthy aging in the country.

Key Companies Profiled in This Report:

• KD Pharma Group
• The Archer Daniels Midland Company
• Corbion NV
• Novasep Holding SAS
• Neptune Wellness Solutions
• BASF SE
• Clover Corporation Ltd
• Croda International Plc
• Novotech Nutraceuticals
• Omega Protein Corporation
• Cargill Inc.
• Epax Norway AS
• GC Rieber Oils AS
• Pharma Marine AS
• Copeinca ASA

Market Competition

In this highly competitive market, the success of top companies hinges on their strategic marketing efforts, which play a pivotal role in determining their fate.

• In 2018, KD Pharma Group introduced two of its DHA and EPA Omega-3 ingredients designed for various uses, spanning from food and drinks to dietary supplements, infant nutrition, and animal feed.
• In June 2021, Polaris presented Omegavie DHA 800 Sensory Qualitysilver 5, a high-potency microalgae-derived DHA ingredient. Sourced from Schizochytrium sp., this algae oil is abundant in proteins, pigments, vitamins, and enzymes.

Winning strategies

• Developing omega-3 supplements with very high levels of EPA and DHA is a strong strategy in the EPA and DHA omega-3 market. This is because EPA and DHA offer proven health benefits, especially for heart and brain health.
• It’s wise for companies to invest in algal-based supplements due to the growing popularity of plant-based diets. These supplements, sourced from microalgae, cater to the rising demand for vegetarian and vegan-friendly options.
• The top players should create omega-3 products that align with medical nutrition and dietary guidelines. They should focus on tailoring these products to meet the specific needs of individuals with different health conditions, such as heart health or cognitive function.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=4050

Country-wise Analysis:

What factors are affecting the US market for EPA and DHA omega-3 supplements?

Large Base of Health-Conscious Consumers and Favorable Regulatory Support

As Americans become more health conscious, the market for EPA and DHA omega-3 components is expanding in a positive way. The demand for supplements and foods that have been enhanced with omega-3 fatty acids is rising as more Americans become aware of their health benefits.

The EPA and DHA omega-3 consumption in food or supplements may lower the risk of coronary heart disease and hypertension, according to qualified health claims that were approved by the US FDA on June 19, 2019.

Omega-3 health claims, particularly those relating to EPA and DHA, have also been approved by the US Food and Drug Administration (FDA) and can now be used in marketing and labeling. Its regulatory backing is boosting consumer confidence and boosting sales of EPA and DHA omega-3-based products.